DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20163227

A comparative study of efficacy and safety of combination of indacaterol and tiotropium versus formoterol and budesonide in moderate to severe COPD

Manohar M. Bende, Sujata Dudhgaonkar, Raviraj S. Jagdhani

Abstract


Background: COPD patients suffer persistent airflow obstruction and exacerbation despite treatment with LABA and ICS. Presently LABA+LAMA is least tested combination hence we want to compare efficacy and safety of combination of indacaterol and tiotropium versus formoterol and budesonide in moderate to severe COPD.

Methods: This was an open labelled, parallel group trial involving 60 patients. of moderate to severe COPD having baseline postbronchodilator FEV1 ≥30% predicted and less than 80% predicted already on some kind of COPD treatment were included and, efficacy on lung function (FEV1)  and  safety in two  groups, indacaterol+tiotropium once daily dpi versus formoterol+budesonide twice daily bd dpi were testedi24 hours postdose (trough) DPI in symptomatic patients of COPD of moderate to severe grade. Statistical analysis was done using repeated measures of ANOVA followed by Turkeys test. P value less than 0.05 were considered statistically significant.

Results: Patient with baseline/post bronchodilator FEV1 ≥30% predicted and less than 80% predicted were included. The mean age was 55±5 years. At 4 weeks mean±SEM in peak FEV1 in indacaterol+tiotropium was 85.77±4.002 and in formoterol+budesonide was 77.33±5.598. At 12 weeks, mean ±SEM in peak FEV1 in indacaterol+tiotropium was 112.30±4.69 and formoterol+budesonide was 103±6.35. At 24 weeks, mean ±SEM in peak FEV1 in indacaterol+tiotropium= 125.3±5.18 and formoterol+budesonide=112.7±5.89. Adverse events were less in indacaterol+tiotropium group. No serious adverse event occurred. Indacaterol+tiotropium once daily is efficacious and safe as compared to formoterol+budesonide twice daily with less exacerbation.

Conclusions: In patients having poorly controlled COPD despite background therapy (LABA, etophylline+theophylline, etc.) the introduction of indacaterol+tiotropium once daily compared to formoterol+budesonide twice daily DPI significantly improved the FEV1 by sustained bronchodilation, decreased exacerbation and is safe. Further studies are needed to assess quality of life and cost analysis.


Keywords


COPD, Indacaterol + Tiotropium, Formoterol + Budesonide, FEV1

Full Text:

PDF

References


Decramer M, Agusti AG, Bourbeau J, Celli BR, Chen R, Criner G et al. Global strategy for diagnosis, management and prevention of COPD. 2016. Available at: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2016.pdf.

Nobuyuki H. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes. Int J Chron Obstruct Pulmon Dis. 2015;10:1093-102.

Chapman KR, Rennard SI, Dogra A, Owen R, Lassen C, Kramar B; INDORSE Study Investigators. Long term efficacy and safety of indacaterol, a long acting beta2 agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest. 2011;140(1):68-75.

Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, Kramer B. INLIGHT-2 study investigators. Once daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011;37(2):273-9.

Cope S, Capkun-Niggli G, Gale R, Lassen C, Owen R, Ouwens MJ, Bergman G, Jansen JP. Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison. Value health. 2012;15(3):524-33.

Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B. INVOLVE study investigators. Efficacy of a new once-daily long acting inhaled beta2-agonist indacaterol versus twice daily formoterol in COPD. Thorax. 2010;65(6):473-9.

Mahler DA, D’Urzo A, Bateman ED, Ozkan SA, White T, Peckitt C, Lassen C, Kramer B; INTRUST-1 and INTRUST-2 study investigators. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone. a randomized, double blind comparison. Thorax. 2012;67(9):781-8.

Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B. Effiacy and tolerability of indacaterol 75mcg once daily in patients aged ≥ than 40 years with COPD: results from 2 double-blind, placebo-controlled 12-week studies. Clin Ther. 2011;33(12):1974-84.

Abebaw MY, Martin JC, Nicola AH. Ten years of tiotropium: clinical impact and patient perspectives. Int J Chron Obstruct Pulmon Dis. 2013;8:117-25.

Matsushima S, Inui N, Yasui H, Kono M, Nakamura Y, Toyoshima M, Shirai T, Suda T. Indacaterol an tiotropium combination therapy in patients with COPD. Pulm Pharmacol Ther. 2015;30:11-5.

Jutta B, Kai MB: LABA in the management of COPD: focus on indacaterol. Int J Chron Obstruct Pulmon Dis. 2011;6:237-43.

Worth H, Chung KF, Felser JM, Hu H, Rueeqq P. Cardio and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med. 2011;105(4):571-9.

Bateman ED, Ferguson GT, Barnes N. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484-94.

Mahler DA, D’Urzo A, Bateman ED. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax. 2012;67:781-8.

Decramer M, Dahl R, Kornmann O, Korn S, Lawrence D, McBryan D. Effects of long acting bronchodilators in COPD patients according to COPD severity and ICS use. Respiratory Medicine. 2013;107(2):223-32.

Mahler DA, Kerstjens AM, Donohue JF, Buhl R, Lawrence D, Altman P. Indacaterol vs Tiotropium in COPD patients classified as GOLD A and GOLD B. 2015. Available at: http://dx.doi.org/10.1016/j.rmed.2015.05.012.

Katzung BG, Trevor AJ. Basic and Clinical Pharmacology. 13th ed. ISBN-13: 978-0071825054.